Renoprotection and its association with eGFR and renal functional reserve
DOI:
https://doi.org/10.22141/2307-1257.7.4.2018.148512Keywords:
chronic kidney disease, eGFR, functional renal reserve, renoprotection, RAAS blockersAbstract
Renoprotection is a system of measures for primarily pharmacological control, contributing to the continued preservation of renal function. When choosing renoprotection tactics, it is necessary to consider not only the estimated GFR (using the EPI formula), but also a functional renal reserve. The method of determining the renal reserve with oral administration of 0.45–0.50% sodium chloride solution at the rate of 0.5 % of body weight is considered to be physiologically substantiated. The renal reserve determining based on this technique as a routine method for examining nephrological patients provides additional information not only on the number of functioning nephrons, but also on their condition. A differentiated approach to prescribing renoprotective agents has been proposed, taking into account the stage of the disease and the functional renal reserve for maximum preservation of functioning nephrons.Downloads
References
Perico N, Codreanu I, Schieppati A, Remuzzi G. The fu-ture of renoprotection. Kidney Int Suppl. 2005 Aug;(97):S95-101. doi:10.1111/j.1523-1755.2005.09716.x.
Duke GJ. Renal protective agents: a review. Crit Care Re-susc. 1999 Sep;1(3):265-75.
Bamgbola O. Review of vancomycin-induced renal toxic-ity: an update. Ther Adv Endocrinol Metab. 2016 Jun;7(3):136-47. doi: 10.1177/2042018816638223.
van Baar MJB, van Raalte DH, Muskiet MHA. GLP-1 re-ceptor agonists, CKD, and eGFR trajectory. Lancet Diabetes Endocri-nol. 2018 Oct;6(10):764-765. doi: 10.1016/S2213-8587(18)30241-9.
Ratanasrimetha P, Quirich M, Phisitkul S. Renal function-al reserve. The Southwest Respiratory and Critical Care Chronicles. 2018;6(25):26-30. doi: 10.12746/swrccc.v6i25.480.
Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. Pediatr Nephrol. 2014 Feb;29(2):193-202. doi: 10.1007/s00467-013-2494-8.
Molitoris BA. Rethinking CKD Evaluation: Should We Be Quantifying Basal or Stimulated GFR to Maximize Precision and Sen-sitivity? Am J Kidney Dis. 2017 May;69(5):675-683. doi: 10.1053/j.ajkd.2016.11.028.
Hozhenko AІ, Kravchuk AV, Nikitenko OP, Moskolenko OM, Sirman VM. Funktsіonal'nii nirkovii rezerv: Monografіia [Re-nal functional reserve. Monograph]. Odesa: Feniks; 2015. 180 p. (in Ukrainian).
Ivanov DD., Gozhenko AI. Nephrology «under the micro-scope» - Renal functional reserve. Ukraїns'kij medichnij chasopis. 2018;(125):74-75. (in Russian).
Hozhenko AI, Kravchuk AV, Sirman VM, Nikitenko OP, Romaniv LV. Functional renal reserve: physiological value of renal reserve and substantiation of the method of its determination. Pocki. 2015;(14):7-11. doi: 10.22141/2307-1257.0.4.14.2015.74890. (in Ukrainian).
Ivanov DD. Renin-angiotensin system blockers and re-nal functional reserve. Is there a limit of renoprotection? Pocki. 2015;(14):12-15. doi: 10.22141/2307-1257.0.4.14.2015.74891. (in Ukrainian).
Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. An-giotensin-Converting Enzyme Inhibitors in Hypertension To Use or Not to Use? J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
Ivanov DD, Kuryata OV, Garmysh IP. Renin angioten-sin-aldosterone system blockers: chronic kidney disease and car-diovascular risk. Pocki. 2018;7(2):81-90. doi: 10.22141/2307-1257.7.2.2018.127393.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Oct 4. pii: dci180033. doi: 10.2337/dci18-0033.От
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 D.D. Ivanov, A.I. Gozhenko, L.N. Savitskaya
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
